Clinical Trial Update: Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus [NA]

View source ↗

Summary

A clinical trial evaluating anti-CD19 CAR-T cell therapy for moderate to severe active systemic lupus erythematosus has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Safety, Effective | NA | Status: SUSPENDED